For This Week in Cardiology March 24, 2017, Dr John Mandrola comments on the following cardiology news and features stories:
ABSORB-3 at 2 Years: More CV Events With Absorb BVS vs Xience
Meds Sans PCI Judged Okay for Chronic Total Occlusions in DECISION-CTO, but Methods Questioned
Higher Subclinical Leaflet Thrombosis Risk With TAVR Than SAVR, Dual Antiplatelets Not Protective
EINSTEIN CHOICE: Rivaroxaban Beats Aspirin for VTE Recurrence
Rivaroxaban Doesn't Increase Post-ACS Bleeding vs Aspirin: GEMINI-ACS-1 Trial
Features:
Chief Cardiology Correspondent
John M Mandrola, MD, Clinical Electrophysiologist, Baptist Medical Associates, Louisville, Kentucky
John M Mandrola, MD, has disclosed no relevant financial relationships.
© 2017 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mar 24 Cardiology News Podcast - Medscape - Mar 24, 2017.
Comments